person · Reporting owner

FOEHR MATTHEW W

Disclosed activity across 5 companies

Tapewire entity: 53388
SEC CIK: 0001237556

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776	Director	January 21, 2020	April 23, 2020
OmniAb, Inc.OABI · Entity 5294	Director · President and CEO	April 07, 2026	April 08, 2026
Viking Therapeutics, Inc.VKTX · Entity 4067	Director	January 02, 2026	January 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FF EAI Robotics Ecosystem Inc.

Report date January 21, 2020 · Filed April 23, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	138,635	Ending reported balance After 2020-04-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-01-21 · Conversion · Acquired 76,923 · Balance 100,174 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Row 2 · 2020-04-10 · Grant · Acquired 38,461 · Balance 138,635 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.
Series B convertible preferred stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.30	Direct	0	Reported balance After 2020-01-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-21 · Conversion · Disposed 100 · Balance 0 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.
Warrant Shares (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2023-11-05	Direct	0	Reported balance After 2020-04-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-04-10 · Disposition to issuer · Disposed 38,461 · Balance 0 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.

F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.

OmniAb, Inc.

Report date April 07, 2026 · Filed April 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,420,492	Ending reported balance After 2026-04-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-04-07 · Exercise / conversion · Acquired 36,459 · Balance 4,439,736 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 19,244 · Balance 4,420,492 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	309,376	Reported balance After 2026-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-07 · Exercise / conversion · Disposed 36,459 · Balance 309,376 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Viking Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.00001 per shareSEC Table I · non-derivative	Direct	135,186	Ending reported balance After 2026-01-02 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-01-02 · Exercise / conversion · Acquired 16,000 · Balance 148,036 Row 2 · 2026-01-02 · Sale · Disposed 16,000 · Balance 132,036 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-01-02 · Grant · Acquired 3,150 · Balance 135,186 F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2026-01-04	Direct	0	Reported balance After 2026-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-02 · Exercise / conversion · Disposed 16,000 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02	Direct	20,400	Reported balance After 2026-01-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LIGAND PHARMACEUTICALS INC

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	162,187	Reported balance After 2022-11-01 transaction · row 1 1 source row Row 1 · 2022-11-01 · Disposition to issuer · Disposed 20,304 · Balance 162,187 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05	Direct	0	Reported balance After 2022-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-01 · Disposition to issuer · Disposed 34,214 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.

F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

OmniAb Operations, Inc.

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	212,362	Reported balance After 2022-11-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-11-01 · Grant · Acquired 26,193 · Balance 212,362 F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-11-01 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2022-11-01 · Disposition to issuer · Disposed 212,362 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05	Direct	60,878	Reported balance After 2022-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-01 · Grant · Acquired 60,878 · Balance 60,878 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05	Direct	0	Reported balance After 2022-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-01 · Disposition to issuer · Disposed 60,878 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2024-02-12	Direct	0	Reported balance After 2022-11-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-11-01 · Disposition to issuer · Disposed 55,222 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10	Direct	0	Reported balance After 2022-11-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-11-01 · Disposition to issuer · Disposed 35,258 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11	Direct	0	Reported balance After 2022-11-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-11-01 · Disposition to issuer · Disposed 22,660 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24	Direct	0	Reported balance After 2022-11-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-11-01 · Disposition to issuer · Disposed 21,271 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02	Direct	0	Reported balance After 2022-11-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-11-01 · Disposition to issuer · Disposed 17,711 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11	Direct	0	Reported balance After 2022-11-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-11-01 · Disposition to issuer · Disposed 29,861 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13	Direct	0	Reported balance After 2022-11-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-11-01 · Disposition to issuer · Disposed 29,012 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03	Direct	0	Reported balance After 2022-11-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-11-01 · Disposition to issuer · Disposed 11,475 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.

F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.

F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.

F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.

F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

F6: The stock option is fully vested and exercisable.

F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.

F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.

F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 07, 2026 Filed Apr 8, 2026 00:26 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	36,459	$0.00	$0.00	Disclosure SEC source: 0001628280-26-024136 · wk-form4_1775607981.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,376 Underlying: Common Stock · 36,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. Read SEC document
April 07, 2026 Filed Apr 8, 2026 00:26 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	19,244	$1.49	$28,673.56	Disclosure SEC source: 0001628280-26-024136 · wk-form4_1775607981.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,420,492 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 07, 2026 Filed Apr 8, 2026 00:26 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	36,459	$0.00	$0.00	Disclosure SEC source: 0001628280-26-024136 · wk-form4_1775607981.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,439,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
February 18, 2026 Filed Feb 18, 2026 23:34 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	1,562,500	$0.00 Strike: $1.71	$0.00	Disclosure SEC source: 0001237556-26-000001 · wk-form4_1771457685.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,562,500 Underlying: Common Stock · 1,562,500 shares Expires 2036-02-18 F6 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
February 18, 2026 Filed Feb 18, 2026 23:34 UTC	OmniAb, Inc. OABI · Entity 5294	GrantRestricted Stock Units · Derivative	156,250	$0.00	$0.00	Disclosure SEC source: 0001237556-26-000001 · wk-form4_1771457685.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,835 Underlying: Common Stock · 156,250 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSU grant vests in three substantially equal annual installments beginning on February 18, 2027. F5 · derivative.expiration_date: The RSU grant vests in three substantially equal annual installments beginning on February 18, 2027. Read SEC document
February 18, 2026 Filed Feb 18, 2026 23:34 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	58,333	$0.00	$0.00	Disclosure SEC source: 0001237556-26-000001 · wk-form4_1771457685.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,585 Underlying: Common Stock · 58,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 18, 2026. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 18, 2026. Read SEC document
February 18, 2026 Filed Feb 18, 2026 23:34 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	30,843	$1.71	$52,741.53	Disclosure SEC source: 0001237556-26-000001 · wk-form4_1771457685.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,403,277 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.73. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 18, 2026 Filed Feb 18, 2026 23:34 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	58,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001237556-26-000001 · wk-form4_1771457685.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,434,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 18, 2026. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
February 17, 2026 Filed Feb 17, 2026 23:22 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	20,754	$1.70	$35,281.80	Disclosure SEC source: 0001628280-26-008709 · wk-form4_1771370563.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,375,787 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.79. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 16, 2026 Filed Feb 17, 2026 23:22 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	36,458	$0.00	$0.00	Disclosure SEC source: 0001628280-26-008709 · wk-form4_1771370563.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,918 Underlying: Common Stock · 36,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 16, 2025. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 16, 2025. Read SEC document
February 16, 2026 Filed Feb 17, 2026 23:22 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	36,458	$0.00	$0.00	Disclosure SEC source: 0001628280-26-008709 · wk-form4_1771370563.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,396,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 16, 2025. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
January 02, 2026 Filed Jan 6, 2026 01:25 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	20,400	$0.00 Strike: $35.42	$0.00	Disclosure SEC source: 0001193125-26-003109 · ownership.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-01-02 Read SEC document
January 02, 2026 Filed Jan 6, 2026 01:25 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	Exercise / conversionStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $3.33	$0.00	Disclosure SEC source: 0001193125-26-003109 · ownership.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2026 Filed Jan 6, 2026 01:25 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantCommon Stock, par value $0.00001 per share	3,150	$0.00	$0.00	Disclosure SEC source: 0001193125-26-003109 · ownership.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,186 F2 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. Read SEC document
January 02, 2026 Filed Jan 6, 2026 01:25 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	SaleCommon Stock, par value $0.00001 per share	16,000	$35.11	$561,694.40	Disclosure SEC source: 0001193125-26-003109 · ownership.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,036 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 02, 2026 Filed Jan 6, 2026 01:25 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	Exercise / conversionCommon Stock, par value $0.00001 per share	16,000	$3.33	$53,280.00	Disclosure SEC source: 0001193125-26-003109 · ownership.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 08, 2025 Filed Dec 9, 2025 14:01 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	13,666	$1.96	$26,785.36	Disclosure SEC source: 0001237556-25-000013 · wk-form4_1765288871.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,360,083 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.94 to $2.01. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 07, 2025 Filed Dec 9, 2025 14:01 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	26,554	$0.00	$0.00	Disclosure SEC source: 0001237556-25-000013 · wk-form4_1765288871.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,376 Underlying: Common Stock · 26,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on December 7, 2023. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on December 7, 2023. Read SEC document
December 07, 2025 Filed Dec 9, 2025 14:01 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	26,554	$0.00	$0.00	Disclosure SEC source: 0001237556-25-000013 · wk-form4_1765288871.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,373,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on December 7, 2023. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: The total includes 5,208 shares acquired on November 28, 2025, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document
August 26, 2025 Filed Aug 26, 2025 20:02 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	540,540	$1.85	$999,999.00	Disclosure SEC source: 0001237556-25-000009 · wk-form4_1756238569.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,341,987 F1 · kind: On August 26, 2025, the reporting person acquired 540,540 shares of common stock of OmniAb, Inc. in a private placement transaction pursuant to a Securities Purchase Agreement. The shares were purchased at a price of $1.85 per share, which represented the closing price of the issuer's common stock on August 22, 2025. F2 · balance_after: The total includes 5,211 shares acquired on May 30, 2025, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document
April 11, 2025 Filed Apr 14, 2025 23:26 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	Exercise / conversionStock Option (Right to Buy) · Derivative	20,786	$0.00 Strike: $8.00	$0.00	Disclosure SEC source: 0000950170-25-053867 · ownership.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,786 shares Expires 2025-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 11, 2025 Filed Apr 14, 2025 23:26 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	Exercise / conversionCommon Stock, par value $0.00001 per share	20,786	$8.00	$166,288.00	Disclosure SEC source: 0000950170-25-053867 · ownership.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 07, 2025 Filed Apr 8, 2025 00:17 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	36,458	$0.00	$0.00	Disclosure SEC source: 0001628280-25-016993 · wk-form4_1744071457.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,930 Underlying: Common Stock · 36,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. Read SEC document
April 07, 2025 Filed Apr 8, 2025 00:17 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	19,382	$2.00	$38,764.00	Disclosure SEC source: 0001628280-25-016993 · wk-form4_1744071457.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,796,236 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.08. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 07, 2025 Filed Apr 8, 2025 00:17 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	36,458	$0.00	$0.00	Disclosure SEC source: 0001628280-25-016993 · wk-form4_1744071457.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,815,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
February 19, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	19,522	$3.67	$71,645.74	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,779,160 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.71. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document
February 18, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option (right to buy) · Derivative	1,050,000	$0.00 Strike: $3.66	$0.00	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · derivative · entry 8 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,000 Underlying: Common Stock · 1,050,000 shares Expires 2035-02-18 F8 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
February 18, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	GrantRestricted Stock Units · Derivative	175,000	$0.00	$0.00	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · derivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,388 Underlying: Common Stock · 175,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSU grant vests in three substantially equal annual installments beginning on February 18, 2026. F7 · derivative.expiration_date: The RSU grant vests in three substantially equal annual installments beginning on February 18, 2026. Read SEC document
February 18, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	13,964	$3.68	$51,387.52	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,798,682 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.83. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 16, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	36,458	$0.00	$0.00	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · derivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,388 Underlying: Common Stock · 36,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 16, 2025. F3 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 16, 2025. Read SEC document
February 16, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	36,458	Not disclosed	Not disclosed	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,812,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 16, 2025. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	26,549	$0.00	$0.00	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,846 Underlying: Common Stock · 26,549 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 15, 2023. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 15, 2023. Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:51 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	26,549	Not disclosed	Not disclosed	Disclosure SEC source: 0001846253-25-000013 · wk-form4_1740016271.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,776,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 15, 2023. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
January 21, 2025 Filed Jan 22, 2025 22:40 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	41,811	$3.24	$135,467.64	Disclosure SEC source: 0001846253-25-000004 · wk-form4_1737585619.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,749,639 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.27. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 17, 2025 Filed Jan 22, 2025 22:40 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	77,003	$0.00	$0.00	Disclosure SEC source: 0001846253-25-000004 · wk-form4_1737585619.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,791,450 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted on 07/05/2022 and were eligible to vest based on the Issuer's achievement of certain performance objectives during the performance period ending December 31, 2024. On January 17, 2025, the Human Capital Management and Compensation Committee of the Board of Directors of the Issuer certified the Issuer's achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
January 02, 2025 Filed Jan 7, 2025 01:12 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	18,800	$0.00 Strike: $41.12	$0.00	Disclosure SEC source: 0000950170-25-002481 · ownership.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 18,800 shares Expires 2035-01-02 Read SEC document
December 09, 2024 Filed Dec 10, 2024 21:44 UTC	OmniAb, Inc. OABI · Entity 5294	SaleCommon Stock	13,634	$4.13	$56,308.42	Disclosure SEC source: 0001846253-24-000097 · wk-form4_1733867055.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,714,447 F4 · kind: Represents a mandatory sale of shares to satisfy tax withholding obligations, upon the vesting and settlement of restricted stock units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.04 to $4.16. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 07, 2024 Filed Dec 10, 2024 21:44 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	26,555	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001846253-24-000097 · wk-form4_1733867055.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,395 Underlying: Common Stock · 26,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on December 7, 2023. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on December 7, 2023. Read SEC document
December 07, 2024 Filed Dec 10, 2024 21:44 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	26,555	Not disclosed	Not disclosed	Disclosure SEC source: 0001846253-24-000097 · wk-form4_1733867055.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,728,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on December 7, 2023. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: The total includes 2,926 shares acquired on November 29, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document
November 25, 2024 Filed Nov 26, 2024 21:41 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionStock Option (right to buy) · Derivative	68,360	$0.00 Strike: $3.75	$0.00	Disclosure SEC source: 0001846253-24-000090 · wk-form4_1732657271.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,484 Underlying: Common Stock · 68,360 shares Expires 2033-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 25, 2024 Filed Nov 26, 2024 21:41 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionStock Option (right to buy) · Derivative	31,074	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0001846253-24-000090 · wk-form4_1732657271.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,371 Underlying: Common Stock · 31,074 shares Expires 2032-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 25, 2024 Filed Nov 26, 2024 21:41 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	68,360	$3.75	$256,350.00	Disclosure SEC source: 0001846253-24-000090 · wk-form4_1732657271.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,698,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2024 Filed Nov 26, 2024 21:41 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	31,074	$3.68	$114,352.32	Disclosure SEC source: 0001846253-24-000090 · wk-form4_1732657271.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,630,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2024 Filed Jun 27, 2024 20:55 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionStock Option (right to buy) · Derivative	41,015	$0.00 Strike: $3.75	$0.00	Disclosure SEC source: 0001846253-24-000058 · wk-form4_1719521703.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,844 Underlying: Common Stock · 41,015 shares Expires 2033-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
June 27, 2024 Filed Jun 27, 2024 20:55 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionStock Option (right to buy) · Derivative	18,644	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0001846253-24-000058 · wk-form4_1719521703.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,445 Underlying: Common Stock · 18,644 shares Expires 2032-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
June 27, 2024 Filed Jun 27, 2024 20:55 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	41,015	$3.75	$153,806.25	Disclosure SEC source: 0001846253-24-000058 · wk-form4_1719521703.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,599,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2024 Filed Jun 27, 2024 20:55 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	18,644	$3.68	$68,609.92	Disclosure SEC source: 0001846253-24-000058 · wk-form4_1719521703.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,558,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total includes 2,842 shares acquired on May 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document
May 24, 2024 Filed May 28, 2024 21:55 UTC	OmniAb, Inc. OABI · Entity 5294	PurchaseCommon Stock	240,000	$4.42	$1,059,840.00	Disclosure SEC source: 0001846253-24-000036 · wk-form4_1716933349.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,536,665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.32 to $4.49. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 07, 2024 Filed Apr 9, 2024 22:38 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	36,458	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0002001011-24-000045 · edgardoc.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,950 Underlying: Common Stock · 36,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. Read SEC document
April 07, 2024 Filed Apr 9, 2024 22:38 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	18,477	$5.31	$98,112.87	Disclosure SEC source: 0002001011-24-000045 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,170,397 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported RSUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.